KYNB
Kyntra Bio, Inc.
There isn't enough reported data to score KYNB yet.
KYNB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
KYNB's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
KYNB PE Valuation
KYNB has no meaningful PE right now: it lost money over the past year.
KYNB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect KYNB's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
KYNB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $45.20 | +$45.58 |
| Q1 2026 | $40.36 | +$42.86 |
| Q4 2025 | $45.37 | +$57.37 |
| Q3 2025 | $53.48 | +$83.98 |
| Q2 2025 | -$0.38 | +$42.12 |
| Q1 2025 | -$2.50 | +$58.50 |
| Q4 2024 | -$12.00 | +$61.00 |
| Q3 2024 | -$30.50 | +$46.00 |
KYNB has returned to profit: it earned $45.20 per share over the past year, after losing money the year before.
KYNB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $3.7M | +36% |
| Q2 2025 | $1.3M | -97% |
| Q1 2025 | $2.7M | -95% |
| Q3 2024 | $46.3M | +15% |
| Q2 2024 | $50.6M | +14% |
| Q1 2024 | $55.9M | +55% |
| Q4 2023 | $27.1M | -21% |
| Q3 2023 | $40.1M | +155% |
KYNB's revenue has slid since its 2021 peak: −$1M last quarter, down 154% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -370% | +175 points |
| Q4 2025 | -1058% | N/A |
| Q2 2025 | -894% | -873 points |
| Q1 2025 | -545% | -489 points |
| Q3 2024 | -36% | +122 points |
| Q2 2024 | -22% | +177 points |
| Q1 2024 | -56% | +155 points |
| Q4 2023 | -200% | -7.2 points |
KYNB's operating margin was −370% last quarter, down 333 points from the same quarter a year ago.
KYNB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4M | -132% |
| Q1 2026 | -$13.9M | -614% |
| Q4 2025 | -$18.3M | +$12.3M |
| Q3 2025 | -$1.9M | +$6.6M |
| Q2 2025 | $12.7M | +$52.6M |
| Q1 2025 | $2.7M | +$62M |
| Q4 2024 | -$30.6M | -$12M |
| Q3 2024 | -$8.5M | +$76.8M |
KYNB has burned cash in almost every quarter: −$38M over the past year, against −$24M the year before.
KYNB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1K shares |
| 1 year | +0.1% | +6K shares |
| 3 years | +3.6% | +139K shares |
| 5 years | +9.7% | +357K shares |
| Available history | +16% | +568K shares |
KYNB has 4M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $5,000 |
| Q4 2024 | — |
KYNB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2019 | -4.7x | Net Cash |
KYNB has more cash than debt.
KYNB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.1 | Oversold |
| Stochastic | 3.4 | Oversold |
KYNB's weekly RSI is 25 (oversold) and its Stochastic is 3 (oversold).
KYNB PE vs Healthcare Sector
| Metric | KYNB | Sector median | Relative |
|---|---|---|---|
| PE | 0.1x | 26x | 100% below |
| PE % | 0 | 29 | 29 pts below |
KYNB has no meaningful PE right now: it lost money over the past year.
KYNB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.09 | 29% below |
| 20 week MA | $6.52 | 45% below |
| 50 week MA | $7.17 | 50% below |
| 100 week MA | $8.50 | 58% below |
| 200 week MA | $70.4 | 95% below |
KYNB is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
KYNB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,122.3 | $1,010.3 | -10% |
| 2021 | $1,010.3 | $384.8 | -62% |
| 2022 | $384.8 | $390.3 | +1.4% |
| 2023 | $390.3 | $22.2 | -94% |
| 2024 | $22.2 | $14.5 | -35% |
| 2025 | $14.5 | $8.90 | -39% |
| 2026 YTD | $8.90 | $3.59 | -60% |
KYNB has finished three years in a row lower, and it's down 60% so far in 2026.